Scientific Sessions 2024  /  Hot Debates in Heart Failure  /  PRO: Lightening the Load: Use of GLP-1 Receptor Agonists in Heart Failure
Logo

American Heart Association

  2
  0

Final ID:

PRO: Lightening the Load: Use of GLP-1 Receptor Agonists in Heart Failure

  • Vaduganathan, Muthiah  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Borlaug, Barry  ( MAYO CLINIC , Rochester , Minnesota , United States )
    • Author Disclosures:
    Muthiah Vaduganathan: DO have relevant financial relationships ; Researcher:received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, BMS, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, and participates on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics:Active (exists now) | Barry Borlaug: DO have relevant financial relationships ; Researcher:NIH/NHLBI:Active (exists now) ; Consultant:Imbria:Past (completed) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Edwards Lifesciences:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:Actelion:Past (completed) ; Researcher:Tenax Therapeutics:Active (exists now) ; Researcher:Rivus:Active (exists now) ; Researcher:Novo Nordisk:Active (exists now) ; Researcher:Medtronic:Active (exists now) ; Researcher:Corvia:Active (exists now) ; Researcher:AstraZeneca:Active (exists now) ; Researcher:Axon:Active (exists now) ; Researcher:DoD:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Hot Debates in Heart Failure

Monday, 11/18/2024 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
CON: Lightening the Load: Use of GLP-1 Receptor Agonists in Heart Failure

Nazha Hamdani, Butler Javed

CRISPR Clarity: The Time is Now for Gene Editing in Cardiomyopathy

Musunuru Kiran, Olson Eric

More abstracts from these authors:
COPD and Cardiopulmonary Risk: A Critical Connection

Vaduganathan Muthiah

Effects of Tirzepatide on Cardiorenal End-Organ Damage in Heart Failure and Preserved Ejection Fraction: Insights from the SUMMIT trial

Borlaug Barry

You have to be authorized to contact abstract author. Please, Login
Not Available